The Complex Role of IL-10 in Malignant Ascites: a Review

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2024 Jan 27

PMID 38279997

Authors

Yue Huang

Kangni Zou

Heng Jiang

Zhengyu Li

Affiliations

Soon will be listed here.

Abstract

The emergence of malignant ascites (MA) indicates poor prognoses in patients with ovarian, gastrointestinal, breast, and pancreatic cancer. Interleukin-10 (IL-10) is a pleiotropic cytokine with immunoregulatory effects in tumor microenvironment. The level of IL-10 in MA varied across cancer types and patients, influencing cancer progression and outcomes. Originating from various immune and cancer cells, IL-10 contributes to complex signaling pathways in MA. Systemic IL-10 administration, although the evidence of its efficacy on MA is limited, still emerges as a promising therapeutic strategy because it can increase CD8+ T cells cytotoxicity and invigorate exhausted CD8+ tumor infiltration lymphocytes (TILs) directly. IL-10 signaling blockade also demonstrates great potential when combined with other immunotherapies in MA treatment. We reviewed the levels, origins, and functions of IL-10 in malignant ascites and overviewed the current IL-10 signaling targeting therapies, aiming to provide insights for MA treatment.

Citing Articles

Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer.

Liu X, Xi X, Xu S, Chu H, Hu P, Li D Front Immunol. 2024; 15:1507501.

PMID: 39726592 PMC: 11669709. DOI: 10.3389/fimmu.2024.1507501.

Rewiring the T cell-suppressive cytokine landscape of the tumor microenvironment: a new frontier for precision anti-cancer therapy.

Lopresti L, Tatangelo V, Baldari C, Patrussi L Front Immunol. 2024; 15:1418527.

PMID: 39281678 PMC: 11392891. DOI: 10.3389/fimmu.2024.1418527.

Ascites and Serum Interleukin-10 Levels as a Prognostic Tool for Ovarian Cancer Outcomes.

Guigue P, Brezinov Y, Yasmeen A, Mbarik M, Salvador S, Lau S Cancers (Basel). 2024; 16(16).

PMID: 39199610 PMC: 11352926. DOI: 10.3390/cancers16162840.

References

Hart K, Usherwood E, Berwin B . CX3CR1 delineates temporally and functionally distinct subsets of myeloid-derived suppressor cells in a mouse model of ovarian cancer. Immunol Cell Biol. 2014; 92(6):499-508. PMC: 4211619. DOI: 10.1038/icb.2014.13. View

Adam R, Adam Y . Malignant ascites: past, present, and future. J Am Coll Surg. 2004; 198(6):999-1011. DOI: 10.1016/j.jamcollsurg.2004.01.035. View

Shamskhou E, Kratochvil M, Orcholski M, Nagy N, Kaber G, Steen E . Hydrogel-based delivery of Il-10 improves treatment of bleomycin-induced lung fibrosis in mice. Biomaterials. 2019; 203:52-62. PMC: 6430662. DOI: 10.1016/j.biomaterials.2019.02.017. View

Wu L, Deng Z, Peng Y, Han L, Liu J, Wang L . Ascites-derived IL-6 and IL-10 synergistically expand CD14HLA-DR myeloid-derived suppressor cells in ovarian cancer patients. Oncotarget. 2017; 8(44):76843-76856. PMC: 5652747. DOI: 10.18632/oncotarget.20164. View

Santner-Nanan B, Straubinger K, Hsu P, Parnell G, Tang B, Xu B . Fetal-maternal alignment of regulatory T cells correlates with IL-10 and Bcl-2 upregulation in pregnancy. J Immunol. 2013; 191(1):145-53. PMC: 3690326. DOI: 10.4049/jimmunol.1203165. View

Zou W, Machelon V, Borvak J, Nome F, Isaeva T, Wei S . Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med. 2001; 7(12):1339-46. DOI: 10.1038/nm1201-1339. View

Reinartz S, Finkernagel F, Adhikary T, Rohnalter V, Schumann T, Schober Y . A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome. Genome Biol. 2016; 17(1):108. PMC: 4877997. DOI: 10.1186/s13059-016-0956-6. View

Guo Y, Xie Y, Gao M, Zhao Y, Franco F, Wenes M . Metabolic reprogramming of terminally exhausted CD8 T cells by IL-10 enhances anti-tumor immunity. Nat Immunol. 2021; 22(6):746-756. PMC: 7610876. DOI: 10.1038/s41590-021-00940-2. View

Dai X, Meng J, Deng S, Zhang L, Wan C, Lu L . Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel. Theranostics. 2020; 10(7):3049-3063. PMC: 7053188. DOI: 10.7150/thno.42385. View

10.

Hama S, Nishi T, Isono E, Itakura S, Yoshikawa Y, Nishimoto A . Intraperitoneal administration of nanoparticles containing tocopheryl succinate prevents peritoneal dissemination. Cancer Sci. 2022; 113(5):1779-1788. PMC: 9128176. DOI: 10.1111/cas.15321. View

11.

Reitamo S, Remitz A, Tamai K, Uitto J . Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts. J Clin Invest. 1994; 94(6):2489-92. PMC: 330082. DOI: 10.1172/JCI117618. View

12.

Khong H, Restifo N . Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002; 3(11):999-1005. PMC: 1508168. DOI: 10.1038/ni1102-999. View

13.

Wei S, Kryczek I, Zou L, Daniel B, Cheng P, Mottram P . Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 2005; 65(12):5020-6. DOI: 10.1158/0008-5472.CAN-04-4043. View

14.

Raghavan S, Mehta P, Xie Y, Lei Y, Mehta G . Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments. J Immunother Cancer. 2019; 7(1):190. PMC: 6642605. DOI: 10.1186/s40425-019-0666-1. View

15.

Wehinger J, Gouilleux F, Groner B, Finke J, Mertelsmann R . IL-10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, and Stat5) and their distinct combinatorial assembly in the promoters of selected genes. FEBS Lett. 1996; 394(3):365-70. DOI: 10.1016/0014-5793(96)00990-8. View

16.

Mauri C, Bosma A . Immune regulatory function of B cells. Annu Rev Immunol. 2012; 30:221-41. DOI: 10.1146/annurev-immunol-020711-074934. View

17.

Lech-Maranda E, Bienvenu J, Michallet A, Houot R, Robak T, Coiffier B . Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. Eur Cytokine Netw. 2006; 17(1):60-6. View

18.

Autio K, Oft M . Pegylated Interleukin-10: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics. Curr Oncol Rep. 2019; 21(2):19. DOI: 10.1007/s11912-019-0760-z. View

19.

Labidi-Galy S, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A . Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res. 2011; 71(16):5423-34. DOI: 10.1158/0008-5472.CAN-11-0367. View

20.

Dou A, Fang J . Heterogeneous Myeloid Cells in Tumors. Cancers (Basel). 2021; 13(15). PMC: 8345207. DOI: 10.3390/cancers13153772. View